MALVERN, PA – August 9 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (“RBC”) today announced that it has been awarded a Phase II SBIR grant from the National Institutes of Health to apply its new DiscoveryDot(TM) High Throughput Screening technology for drug discovery.

The $750,000 grant originates from the National Institute of Dental and Craniofacial Research and funds the use of RBC’s DiscoveryDot(TM) microarray technology for high throughput screening of caspases and other proteases. The DiscoveryDot(TM) technology is capable of screening up to 6,600 individual reactions on a 1-by-3 inch glass slide. The one nanoliter reaction volume used by RBC represents one ten thousandth the volume of conventional screening systems, and can potentially save millions of dollars on large scale screening campaigns through reagent savings, process costs, and labor reduction.

Caspases play pivotal roles in regulating cell apoptosis and represent targets of significant interest in craniofacial medicine and other areas. RBC’s ability to print large chemical compound libraries in hundreds of replicate copies for caspase and protease screening can accelerate early stage lead identification at a fraction of the cost of conventional technology.

About Reaction Biology Corporation

Reaction Biology, based in Malvern, Pa., provides high throughput screening services to the biotechnology and pharmaceutical industries. The company uses a patent-pending combination of technologies to perform screening at the nanoliter scale, while preserving quality, speed and simplicity. Combining genomics microarray printing technology and picoliter aerosol deposition, RBC has commercialized a novel technology that drives HTS to new levels of simplicity and efficiency.

More information:

News issued by: Reaction Biology Corporation

# # #

Original Story ID: (644) :: 2005-08-0809-002

Original Keywords: Reaction Biology Corporation, discovery dot, Phase II SBIR Grant for Drug Discovery, National Institutes of Health, High Throughput Screening technology for drug discovery Reaction Biology Corporation

News Source: Reaction Biology Corporation